News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,622 Results
Type
Article (14195)
Company Profile (282)
Press Release (252145)
Section
Business (79501)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50443)
Employer Resources (31)
FDA (5715)
Job Trends (5127)
News (144382)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (911)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21636)
ALS (61)
Alzheimer's disease (826)
Antibody-drug conjugate (ADC) (87)
Approvals (5730)
Artificial intelligence (108)
Autoimmune disease (11)
Automation (5)
Bankruptcy (104)
Best Places to Work (4561)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (19)
Breast cancer (141)
Cancer (1306)
Cardiovascular disease (111)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (307)
Cervical cancer (8)
Clinical research (40895)
Collaboration (497)
Compensation (219)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1363)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1292)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (82)
Earnings (29681)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48142)
Executive appointments (403)
FDA (6336)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (466)
Gene editing (89)
Generative AI (9)
Gene therapy (231)
GLP-1 (357)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6590)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (57)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (202)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (186)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (48)
Medical device (2588)
Medtech (2589)
Mergers & acquisitions (6251)
Metabolic disorders (364)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1195)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1553)
Now hiring (21)
Obesity (185)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (105)
Partnered (8)
Patents (111)
Patient recruitment (66)
Peanut (35)
People (25506)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14439)
Phase II (19026)
Phase III (12032)
Pipeline (726)
Podcasts (46)
Policy (37)
Postmarket research (852)
Preclinical (6062)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (274)
Real estate (1414)
Recruiting (12)
Regulatory (8565)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (91)
Series B (60)
Service/supplier (1)
Sickle cell disease (38)
Southern California (1379)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12141)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (150)
Last 7 days (445)
Last 30 days (1660)
Last 365 days (20056)
2025 (4775)
2024 (20553)
2023 (22415)
2022 (26822)
2021 (27809)
2020 (23359)
2019 (16225)
2018 (11738)
2017 (13747)
2016 (11839)
2015 (14351)
2014 (10394)
2013 (7484)
2012 (7532)
2011 (7615)
2010 (7429)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17227)
Australia (2917)
California (3530)
Canada (1051)
China (324)
Colorado (136)
Connecticut (143)
Delaware (88)
Europe (37031)
Florida (414)
Georgia (108)
Idaho (16)
Illinois (211)
India (8)
Indiana (85)
Iowa (1)
Japan (71)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2785)
Michigan (69)
Minnesota (136)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (886)
New Mexico (12)
New York (957)
North Carolina (520)
North Dakota (4)
Northern California (1553)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (675)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1379)
Tennessee (25)
Texas (408)
Utah (48)
Virginia (68)
Washington D.C. (28)
Washington State (321)
Wisconsin (13)
266,622 Results for "soleno therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Soleno Wins First FDA Approval for Hyperphagia in Prader-Willi Syndrome
Soleno’s Vykat XR is the first drug approved for the rare disease that directly targets its hallmark symptom.
March 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR
March 31, 2025
·
2 min read
Press Releases
Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome
March 27, 2025
·
7 min read
Press Releases
Soleno Therapeutics to Participate in Upcoming February 2025 Investor Conferences
January 30, 2025
·
1 min read
Press Releases
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
February 27, 2025
·
13 min read
Biotech Bay
Soleno Therapeutics to Participate in Upcoming May 2024 Investor Conferences
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences.
May 22, 2024
·
1 min read
Press Releases
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
October 28, 2024
·
1 min read
Press Releases
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
·
1 min read
Biotech Bay
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 24, 2024
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to eight new employees.
June 24, 2024
·
1 min read
Biotech Bay
Soleno Therapeutics Set to Join Russell 3000® Index - June 04, 2024
Soleno Therapeutics, Inc. announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
June 4, 2024
·
4 min read
1 of 26,663
Next
